id stringlengths 1 9 | document_id stringlengths 3 5 | passages listlengths 1 1 | entities listlengths 5 281 | relations listlengths 0 0 | events listlengths 0 0 | coreferences listlengths 0 0 |
|---|---|---|---|---|---|---|
0_chunk_0 | 318 | [
{
"id": "318__text_chunk_0",
"offsets": [
[
0,
6541
]
],
"text": [
"EMEA / H / C / 551 \n PRIALT \n Qu ’ est ce que Prialt ? \n Prialt est une solution pour perfusion contenant le principe actif ziconotide , à des concentrations de 100 ou 25 microgrammes par millili... | [
{
"id": "318_T1",
"normalized": [
{
"db_id": "C1530575",
"db_name": "UMLS"
}
],
"offsets": [
[
21,
27
]
],
"text": [
"PRIALT"
],
"type": "CHEM"
},
{
"id": "318_T2",
"normalized": [
{
"db_id": "C15... | [] | [] | [] |
0_chunk_1 | 318 | [
{
"id": "318__text_chunk_1",
"offsets": [
[
0,
6576
]
],
"text": [
"Les patients et les médecins doivent être vigilants concernant l ’ apparition de symptômes et signes typiques de méningite . \n Le positionnement intrathécal optimal du cathéter n ’ a pas été établi... | [
{
"id": "318_T237",
"normalized": [
{
"db_id": "C0030705",
"db_name": "UMLS"
}
],
"offsets": [
[
4,
12
]
],
"text": [
"patients"
],
"type": "LIVB"
},
{
"id": "318_T238",
"normalized": [
{
"db_id":... | [] | [] | [] |
0_chunk_2 | 318 | [
{
"id": "318__text_chunk_2",
"offsets": [
[
0,
6564
]
],
"text": [
"L ’ Agence européenne du médicament ( EMEA ) réévaluera chaque année toute nouvelle information qui pourrait être fournie , et si nécessaire cet RCP sera mis à jour . \n De nombreux patients réponda... | [
{
"id": "318_T519",
"normalized": [
{
"db_id": "C0013227",
"db_name": "UMLS"
}
],
"offsets": [
[
25,
35
]
],
"text": [
"médicament"
],
"type": "CHEM"
},
{
"id": "318_T520",
"normalized": [
{
"db_i... | [] | [] | [] |
0_chunk_3 | 318 | [
{
"id": "318__text_chunk_3",
"offsets": [
[
0,
6183
]
],
"text": [
"Des informations détaillées sur ce médicament sont disponibles sur le site internet de l ’ Agence européenne du médicament ( EMEA ) www . emea . europa . eu \n Prialt 25 microgrammes / ml , solution... | [
{
"id": "318_T704",
"normalized": [
{
"db_id": "C0013227",
"db_name": "UMLS"
}
],
"offsets": [
[
35,
45
]
],
"text": [
"médicament"
],
"type": "CHEM"
},
{
"id": "318_T705",
"normalized": [
{
"db_i... | [] | [] | [] |
1 | 345_1 | [
{
"id": "345_1__text",
"offsets": [
[
0,
4712
]
],
"text": [
"EMEA / H / C / 122 \n REFLUDAN \n Qu ’ est-ce que Refludan ? \n Refludan se présente sous forme de poudre , conditionnée en flacon , à faire dissoudre pour obtenir une solution injectable ou perfusable ( ... | [
{
"id": "345_1_T1",
"normalized": [
{
"db_id": "C0661608",
"db_name": "UMLS"
}
],
"offsets": [
[
21,
29
]
],
"text": [
"REFLUDAN"
],
"type": "CHEM"
},
{
"id": "345_1_T2",
"normalized": [
{
"db_id"... | [] | [] | [] |
2 | 345_2 | [
{
"id": "345_2__text",
"offsets": [
[
0,
4051
]
],
"text": [
"EMEA / H / C / 122 \n\n Recommandations standard \n Comme la lépirudine est excrétée et métabolisée en quasi-totalité par le rein ( voir également la rubrique 5 . 2 ), il est nécessaire de connaître l \n ... | [
{
"id": "345_2_T1",
"normalized": [
{
"db_id": "C0772394",
"db_name": "UMLS"
}
],
"offsets": [
[
58,
68
]
],
"text": [
"lépirudine"
],
"type": "CHEM"
},
{
"id": "345_2_T2",
"normalized": [
{
"db_i... | [] | [] | [] |
3 | 345_3 | [
{
"id": "345_3__text",
"offsets": [
[
0,
5531
]
],
"text": [
"EMEA / H / C / 122 \n\n 4 . 3 Contre-indications \n CSL Behring GmbH Emil-von-Behring-Straße 76 35041 Marburg Allemagne \n 25 MENTIONS DEVANT FIGURER SUR L ’ EMBALLAGE EXTERIEUR ET SUR LE CONDITIONNEMENT ... | [
{
"id": "345_3_T1",
"normalized": [
{
"db_id": "C0017480",
"db_name": "UMLS"
}
],
"offsets": [
[
107,
116
]
],
"text": [
"Allemagne"
],
"type": "GEOG"
},
{
"id": "345_3_T2",
"normalized": [
{
"db_... | [] | [] | [] |
4 | 425_1 | [
{
"id": "425_1__text",
"offsets": [
[
0,
6823
]
],
"text": [
"EMEA / H / C / 603 \n TYSABRI \n Qu ’ est-ce que Tysabri ? \n Tysabri est une solution à diluer pour perfusion ( goutte-à-goutte dans une veine ). \n\n Il contient le principe actif natalizumab . \n Dans ... | [
{
"id": "425_1_T1",
"normalized": [
{
"db_id": "C1529600",
"db_name": "UMLS"
}
],
"offsets": [
[
21,
28
]
],
"text": [
"TYSABRI"
],
"type": "CHEM"
},
{
"id": "425_1_T2",
"normalized": [
{
"db_id":... | [] | [] | [] |
5_chunk_0 | 425_2 | [
{
"id": "425_2__text_chunk_0",
"offsets": [
[
0,
4080
]
],
"text": [
"TYSABRI 300 mg est administré en perfusion intraveineuse une fois toutes les 4 semaines . \n TYSABRI n ’ est pas recommandé chez les sujets âgés de plus de 65 ans en raison de l ’ absence de donné... | [
{
"id": "425_2_T1",
"normalized": [
{
"db_id": "C1529600",
"db_name": "UMLS"
}
],
"offsets": [
[
0,
7
]
],
"text": [
"TYSABRI"
],
"type": "CHEM"
},
{
"id": "425_2_T2",
"normalized": [
{
"db_id": "... | [] | [] | [] |
5_chunk_1 | 425_2 | [
{
"id": "425_2__text_chunk_1",
"offsets": [
[
0,
4014
]
],
"text": [
"Les patients devront être informés qu ’ en cas d ’ apparition d ’ une quelconque infection , ils devront prévenir leur médecin qu ’ ils sont traités par TYSABRI . \n Les médecins doivent informer ... | [
{
"id": "425_2_T120",
"normalized": [
{
"db_id": "C0030705",
"db_name": "UMLS"
}
],
"offsets": [
[
4,
12
]
],
"text": [
"patients"
],
"type": "LIVB"
},
{
"id": "425_2_T121",
"normalized": [
{
"db_... | [] | [] | [] |
6_chunk_0 | 425_3 | [
{
"id": "425_3__text_chunk_0",
"offsets": [
[
0,
3866
]
],
"text": [
"L ’ instauration d ’ autres traitements au cours de cette période conduira donc à une exposition concomitante au natalizumab . \n Au cours des essais cliniques , une exposition concomitante de cet... | [
{
"id": "425_3_T1",
"normalized": [
{
"db_id": "C0087111",
"db_name": "UMLS"
}
],
"offsets": [
[
28,
39
]
],
"text": [
"traitements"
],
"type": "PROC"
},
{
"id": "425_3_T2",
"normalized": [
{
"db_... | [] | [] | [] |
6_chunk_1 | 425_3 | [
{
"id": "425_3__text_chunk_1",
"offsets": [
[
0,
4046
]
],
"text": [
"Etant donné que la présence de ces anticorps peut être associée à une diminution de l ’ efficacité du traitement et à une augmentation des réactions d ’ hypersensibilité ou des réactions liées à l... | [
{
"id": "425_3_T103",
"normalized": [
{
"db_id": "C0003241",
"db_name": "UMLS"
}
],
"offsets": [
[
35,
44
]
],
"text": [
"anticorps"
],
"type": "CHEM"
},
{
"id": "425_3_T104",
"normalized": [
{
"d... | [] | [] | [] |
6_chunk_2 | 425_3 | [
{
"id": "425_3__text_chunk_2",
"offsets": [
[
0,
140
]
],
"text": [
"Il semble que , dans la SEP , les lésions apparaissent lorsque les lymphocytes T activés traversent la barrière hémato-encéphalique ( BHE )."
],
"type": null
}
] | [
{
"id": "425_3_T218",
"normalized": [
{
"db_id": "C0026769",
"db_name": "UMLS"
}
],
"offsets": [
[
24,
27
]
],
"text": [
"SEP"
],
"type": "DISO"
},
{
"id": "425_3_T219",
"normalized": [
{
"db_id":... | [] | [] | [] |
7 | 425_4 | [
{
"id": "425_4__text",
"offsets": [
[
0,
7421
]
],
"text": [
"\n\n L ’ interaction entre l ’ intégrine α 4β 1 et ses cibles est une composante importante de l ’ inflammation pathologique cérébrale , qui diminue avec l ’ inhibition de ces interactions . \n Dans le co... | [
{
"id": "425_4_T1",
"normalized": [
{
"db_id": "C0687133",
"db_name": "UMLS"
}
],
"offsets": [
[
7,
18
]
],
"text": [
"interaction"
],
"type": "PHYS"
},
{
"id": "425_4_T2",
"normalized": [
{
"db_i... | [] | [] | [] |
8 | 425_5 | [
{
"id": "425_5__text",
"offsets": [
[
0,
4474
]
],
"text": [
"\n\n Solution diluée \n À conserver au réfrigérateur ( entre 2°C et 8°C ). \n 15 ml de TYSABRI dans un flacon ( verre type I ) muni d ’ un bouchon de caoutchouc ( bromobutyle ) serti avec une bague ( alum... | [
{
"id": "425_5_T1",
"normalized": [
{
"db_id": "C1529600",
"db_name": "UMLS"
}
],
"offsets": [
[
83,
90
]
],
"text": [
"TYSABRI"
],
"type": "CHEM"
},
{
"id": "425_5_T2",
"normalized": [
{
"db_id":... | [] | [] | [] |
9 | 425_6 | [
{
"id": "425_6__text",
"offsets": [
[
0,
5992
]
],
"text": [
"\n\n QU ’ EST-CE QUE TYSABRI ET DANS QUEL CAS EST-IL UTILISE \n TYSABRI est utilisé pour traiter la sclérose en plaques ( SEP ). \n Les symptômes de SEP peuvent varier d ’ un patient à l ’ autre et il est... | [
{
"id": "425_6_T1",
"normalized": [
{
"db_id": "C1529600",
"db_name": "UMLS"
}
],
"offsets": [
[
19,
26
]
],
"text": [
"TYSABRI"
],
"type": "CHEM"
},
{
"id": "425_6_T2",
"normalized": [
{
"db_id":... | [] | [] | [] |
10 | 425_7 | [
{
"id": "425_7__text",
"offsets": [
[
0,
4598
]
],
"text": [
"\n\n Signes évocateurs d ’ éventuels troubles hépatiques : • Jaunisse ( coloration jaune de la peau ou du blanc des yeux ) • Urines anormalement foncées . \n TYSABRI peut également avoir d ’ autres effets... | [
{
"id": "425_7_T1",
"normalized": [
{
"db_id": "C1547188",
"db_name": "UMLS"
}
],
"offsets": [
[
3,
9
]
],
"text": [
"Signes"
],
"type": "DISO"
},
{
"id": "425_7_T2",
"normalized": [
{
"db_id": "C... | [] | [] | [] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.